S M S Hashemi
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Dafni U, Soo R, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J, de Castro J, Coate L, Früh M, Hashemi S, Nadal E, Carcereny E, Sala M, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO Open 2022; 7:100507.
Jun 10, 2022Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Jun 10, 2022ESMO Open 2022; 7:100507
Dafni U, Soo R A, Peters S, Tsourti Zoi, Zygoura P, Vervita K, Han J-Y, de Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo R, Han J, Dafni U, Cho B, Yeo C, Nadal E, Carcereny E, de Castro J, Sala M, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R, Peters S, ETOP 10-16 BOOSTER Collaborators. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol 2021; 33:181-192.
Nov 26, 2021A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Nov 26, 2021Ann Oncol 2021; 33:181-192
Soo R A, Han J-Y, Dafni U, Cho B C, Yeo C M, Nadal E, Carcereny E, de Castro J, Sala M A, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S M S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J-M, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A, Peters S, ETOP 10-16 BOOSTER Collaborators